Emad Babakhanzadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emad Babakhanzadeh has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Majid Nazari
Shahid Sadoughi Univ Med Sci, Dept Med Genet, Yazd, Iran
6 shared publications Ali Khodadadian
Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 shared publications- Nasrin Ghasemi
Abortion Research Center, Reproductive Sciences Institute, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 shared publications Mehdi Hosseinnia
Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran
2 shared publicationsMehrdad Talebi
School of Medicine, Department of Medical Genetic, Shahid Sadoughi University of Medical Science, Yazd, Iran
2 shared publicationsMohammad Yahya Vahidi Mehrjardi
Medical Genetics Research Centre, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2 shared publications
Latest Publications
- 20 August 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- p. 1-12
Circular RNA–Mediated ceRNA networks predict sperm retrieval outcomes in non-obstructive azoospermia
Introduction Non-obstructive azoospermia (NOA) is a severe form of male infertility in which focal spermatogenesis may persist in otherwise functionally impaired testes. Testicular sperm extraction by microdissection (mTESE) remains the standard procedure for sperm retrieval, but its unpredictable success rate emphasizes the urgent need for reliable, non-invasive biomarkers to support clinical decision-making. Recent advances in transcriptomics have highlighted the role of circular RNAs (circRNAs), microRNAs (miRNAs), and their mRNA targets in the formation of competing endogenous RNA networks (ceRNAs) that regulate spermatogenesis. Methods In this study, we identified and validated two novel ceRNA axes, circSH3PXD2A/miR-375-3p/SH3PXD2A and hsa_circ_0037070/miR-487b-3p/ALDH1A3, by integrative bioinformatics and experimental analyses. Results Both SH3PXD2A and ALDH1A3 were significantly upregulated in NOA patients, while their regulatory miRNAs were downregulated, with circRNA partners showing subtype-specific changes. Importantly, the differences in expression correlated with the mTESE results: NOA − patients (failed recovery) showed more extreme dysregulation than NOA + . Receiver operating characteristic (ROC) curve analysis confirmed the diagnostic potential of these markers, with circRNAs and miRNAs showing high discriminatory power (AUC > 0.90). Conclusion Our results demonstrate that dysregulation of circRNA–miRNA–mRNA networks is a key feature of NOA and that circulating circRNAs and miRNAs can serve as minimally invasive biomarkers for predicting sperm retrieval success. These findings not only improve our understanding of the molecular basis of NOA, but also open up new avenues for precision diagnostics in male infertility.
- 20 August 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- p. 1-12
Circular RNA–Mediated ceRNA networks predict sperm retrieval outcomes in non-obstructive azoospermia
Introduction Non-obstructive azoospermia (NOA) is a severe form of male infertility in which focal spermatogenesis may persist in otherwise functionally impaired testes. Testicular sperm extraction by microdissection (mTESE) remains the standard procedure for sperm retrieval, but its unpredictable success rate emphasizes the urgent need for reliable, non-invasive biomarkers to support clinical decision-making. Recent advances in transcriptomics have highlighted the role of circular RNAs (circRNAs), microRNAs (miRNAs), and their mRNA targets in the formation of competing endogenous RNA networks (ceRNAs) that regulate spermatogenesis. Methods In this study, we identified and validated two novel ceRNA axes, circSH3PXD2A/miR-375-3p/SH3PXD2A and hsa_circ_0037070/miR-487b-3p/ALDH1A3, by integrative bioinformatics and experimental analyses. Results Both SH3PXD2A and ALDH1A3 were significantly upregulated in NOA patients, while their regulatory miRNAs were downregulated, with circRNA partners showing subtype-specific changes. Importantly, the differences in expression correlated with the mTESE results: NOA − patients (failed recovery) showed more extreme dysregulation than NOA + . Receiver operating characteristic (ROC) curve analysis confirmed the diagnostic potential of these markers, with circRNAs and miRNAs showing high discriminatory power (AUC > 0.90). Conclusion Our results demonstrate that dysregulation of circRNA–miRNA–mRNA networks is a key feature of NOA and that circulating circRNAs and miRNAs can serve as minimally invasive biomarkers for predicting sperm retrieval success. These findings not only improve our understanding of the molecular basis of NOA, but also open up new avenues for precision diagnostics in male infertility.
- 24 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 325
Circular RNAs in human biology: from splicing noise to master regulators
Circular RNAs (circRNAs) are covalently closed RNA transcripts produced by back-splicing. First identified in plant viroid in 1976, they were long regarded as "splicing noise" or transcriptional byproducts. However, high-throughput sequencing has revealed thousands of circRNAs in eukaryotic cells, indicating that they are widespread and conserved. These molecules lack 5' caps and 3' poly(A) tails, making them resistant to exonucleases. Their circular structure confers exceptional stability, and many circRNAs are expressed in a tissue-specific manner, making them attractive biomarkers. Functionally, circRNAs regulate gene expression at multiple levels. Many act as "sponges" for microRNAs or RNA-binding proteins, modulating mRNA stability and translation; others influence transcription, alternative splicing, or chromatin architecture, and some can be translated into peptides. In human biology, circRNAs have diverse roles: dysregulated circRNAs contribute to tumorigenesis and shape the tumor microenvironment; they are abundant in the brain and implicated in neurodevelopment and neurodegenerative diseases; and they modulate immune responses (for example, via T cells, NK cells, and macrophages). Experimentally, circRNAs are detected by RNase R-enriched RNA sequencing and bioinformatics pipelines that identify unique back-splice junction reads. Predicted circRNAs are then validated by RT-PCR across the circular junction. The stability and versatility of circRNAs have inspired therapeutic applications, such as engineered circRNA vaccines or miRNA sponges. Overall, these findings underscore that circRNAs constitute a powerful and versatile class of gene regulators with significant diagnostic and therapeutic potential, although translating this potential into clinical success requires overcoming current challenges. Nonetheless, significant challenges in delivery, specificity, and immunogenicity remain to be addressed before clinical translation.
- 24 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 325
Circular RNAs in human biology: from splicing noise to master regulators
Circular RNAs (circRNAs) are covalently closed RNA transcripts produced by back-splicing. First identified in plant viroid in 1976, they were long regarded as "splicing noise" or transcriptional byproducts. However, high-throughput sequencing has revealed thousands of circRNAs in eukaryotic cells, indicating that they are widespread and conserved. These molecules lack 5' caps and 3' poly(A) tails, making them resistant to exonucleases. Their circular structure confers exceptional stability, and many circRNAs are expressed in a tissue-specific manner, making them attractive biomarkers. Functionally, circRNAs regulate gene expression at multiple levels. Many act as "sponges" for microRNAs or RNA-binding proteins, modulating mRNA stability and translation; others influence transcription, alternative splicing, or chromatin architecture, and some can be translated into peptides. In human biology, circRNAs have diverse roles: dysregulated circRNAs contribute to tumorigenesis and shape the tumor microenvironment; they are abundant in the brain and implicated in neurodevelopment and neurodegenerative diseases; and they modulate immune responses (for example, via T cells, NK cells, and macrophages). Experimentally, circRNAs are detected by RNase R-enriched RNA sequencing and bioinformatics pipelines that identify unique back-splice junction reads. Predicted circRNAs are then validated by RT-PCR across the circular junction. The stability and versatility of circRNAs have inspired therapeutic applications, such as engineered circRNA vaccines or miRNA sponges. Overall, these findings underscore that circRNAs constitute a powerful and versatile class of gene regulators with significant diagnostic and therapeutic potential, although translating this potential into clinical success requires overcoming current challenges. Nonetheless, significant challenges in delivery, specificity, and immunogenicity remain to be addressed before clinical translation.
- 2 August 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-19
Personalizing cancer therapy: the role of pharmacogenetics in overcoming drug resistance and toxicity
Cancer pharmacogenetics has become a cornerstone of precision oncology. It offers the potential to optimize therapeutic outcomes by tailoring treatments to individual genetic profiles. This review explores the central role of pharmacogenomics in addressing key challenges in cancer therapy, including drug resistance, variability in drug response between patients and chemotherapy-induced toxicity. We highlight key pharmacogenetic markers — such as DPYD, TPMT, UGT1A1, CYP2D6, ERCC1 and XRCC1 — that influence the metabolism, efficacy and toxicity of widely used chemotherapeutic agents. In addition, we discuss the role of ATP-binding cassette transporters (ABC transporters), including ABCB1, ABCG2 and ABCC2, in mediating drug resistance and their importance for personalized treatment strategies. Despite significant progress, the clinical translation of pharmacogenomics still faces several challenges. These include the need for large-scale validation of biomarkers in different populations, the integration of gene-environment interactions and the clarification of ethical and privacy concerns related to genetic testing. New technologies such as next-generation sequencing (NGS), liquid biopsies and artificial intelligence (AI)-based predictive models can overcome these obstacles by enabling real-time monitoring of tumor dynamics and refining personalized treatment protocols. The future of cancer pharmacogenetics lies in the integration of multi-omics data encompassing genomics, epigenomics, transcriptomics and proteomics to provide a comprehensive understanding of tumor biology and drug response. Collaboration between academic institutions, pharmaceutical companies and regulatory authorities is essential to establish standardized protocols for biomarker validation and expand pharmacogenomic databases. In addition, the development of ethical frameworks and patient-centered approaches will ensure the responsible integration of pharmacogenomics into clinical practice. By addressing current challenges and utilizing new technologies, cancer pharmacogenetics holds great promise for advancing precision oncology. This review highlights the importance of personalized medicine in improving therapeutic efficacy, minimizing adverse effects and ultimately improving patient outcomes in the fight against cancer.
- 2 August 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-19
Personalizing cancer therapy: the role of pharmacogenetics in overcoming drug resistance and toxicity
Cancer pharmacogenetics has become a cornerstone of precision oncology. It offers the potential to optimize therapeutic outcomes by tailoring treatments to individual genetic profiles. This review explores the central role of pharmacogenomics in addressing key challenges in cancer therapy, including drug resistance, variability in drug response between patients and chemotherapy-induced toxicity. We highlight key pharmacogenetic markers — such as DPYD, TPMT, UGT1A1, CYP2D6, ERCC1 and XRCC1 — that influence the metabolism, efficacy and toxicity of widely used chemotherapeutic agents. In addition, we discuss the role of ATP-binding cassette transporters (ABC transporters), including ABCB1, ABCG2 and ABCC2, in mediating drug resistance and their importance for personalized treatment strategies. Despite significant progress, the clinical translation of pharmacogenomics still faces several challenges. These include the need for large-scale validation of biomarkers in different populations, the integration of gene-environment interactions and the clarification of ethical and privacy concerns related to genetic testing. New technologies such as next-generation sequencing (NGS), liquid biopsies and artificial intelligence (AI)-based predictive models can overcome these obstacles by enabling real-time monitoring of tumor dynamics and refining personalized treatment protocols. The future of cancer pharmacogenetics lies in the integration of multi-omics data encompassing genomics, epigenomics, transcriptomics and proteomics to provide a comprehensive understanding of tumor biology and drug response. Collaboration between academic institutions, pharmaceutical companies and regulatory authorities is essential to establish standardized protocols for biomarker validation and expand pharmacogenomic databases. In addition, the development of ethical frameworks and patient-centered approaches will ensure the responsible integration of pharmacogenomics into clinical practice. By addressing current challenges and utilizing new technologies, cancer pharmacogenetics holds great promise for advancing precision oncology. This review highlights the importance of personalized medicine in improving therapeutic efficacy, minimizing adverse effects and ultimately improving patient outcomes in the fight against cancer.
- 1 August 2020
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 67 (7) , 454-460
Evaluation of miR-181b and miR-126-5p expression levels in T2DM patients compared to healthy individuals: Relationship with NF-κB gene expression
- 1 August 2020
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 67 (7) , 454-460
Evaluation of miR-181b and miR-126-5p expression levels in T2DM patients compared to healthy individuals: Relationship with NF-κB gene expression
- Open Access
- 1 May 2020
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 13, 185-192
Deficient Expression of DGCR8 in Human Testis is Related to Spermatogenesis Dysfunction, Especially in Meiosis I
Introduction: DiGeorge syndrome critical region gene 8 (DGCR8) contributes to miRNA biogenesis, and defects in its expression could lead to defects in spermatogenesis. Methods: Here, we assess gene and protein expression levels of DGCR8 in the testicular biopsy specimens obtained from men with obstructive azoospermia (OA, n = 19) and various types of non-obstructive azoospermia (NOA) including maturation arrest (MA, n = 17), Sertoli cell-only syndrome (SCOS, n = 20) and hypospermatogenesis (HYPO, 18). Also, samples of men with NOA were divided into two groups based on successful and unsuccessful sperm recovery, NOA+ in 21 patients and NOA− in 34 patients. Results: Examinations disclosed a severe decrease in DGCR8 in samples with MA and SCOS in comparison to OA samples (P < 0.001). Also, the results showed DGCR8 has significantly lower expression in testis tissues of NOA− group in comparison to NOA+ group (p< 0.05). Western blot analysis confirmed that the DGCR8 protein was not expressed in SCOS samples and had a very low expression in MA and HYPO samples. Discussion: The results of this survey showed that DGCR8 is an important gene for the entire spermatogenesis pathway. Moreover, DGCR8 gene plays an important role in the diagnosis of NOA subgroups, and also the expression changes in it might contribute to SCOS or MA phenotypes. This gene with considering other related genes can also be a predictor of sperm retrieval.
- 1 May 2020
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 13, 185-192
Open AccessDeficient Expression of DGCR8 in Human Testis is Related to Spermatogenesis Dysfunction, Especially in Meiosis I
Introduction: DiGeorge syndrome critical region gene 8 (DGCR8) contributes to miRNA biogenesis, and defects in its expression could lead to defects in spermatogenesis. Methods: Here, we assess gene and protein expression levels of DGCR8 in the testicular biopsy specimens obtained from men with obstructive azoospermia (OA, n = 19) and various types of non-obstructive azoospermia (NOA) including maturation arrest (MA, n = 17), Sertoli cell-only syndrome (SCOS, n = 20) and hypospermatogenesis (HYPO, 18). Also, samples of men with NOA were divided into two groups based on successful and unsuccessful sperm recovery, NOA+ in 21 patients and NOA− in 34 patients. Results: Examinations disclosed a severe decrease in DGCR8 in samples with MA and SCOS in comparison to OA samples (P < 0.001). Also, the results showed DGCR8 has significantly lower expression in testis tissues of NOA− group in comparison to NOA+ group (p< 0.05). Western blot analysis confirmed that the DGCR8 protein was not expressed in SCOS samples and had a very low expression in MA and HYPO samples. Discussion: The results of this survey showed that DGCR8 is an important gene for the entire spermatogenesis pathway. Moreover, DGCR8 gene plays an important role in the diagnosis of NOA subgroups, and also the expression changes in it might contribute to SCOS or MA phenotypes. This gene with considering other related genes can also be a predictor of sperm retrieval.
- Open Access
- 31 March 2020
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 47 (1) , 61-67
Upregulation of the RNF8 gene can predict the presence of sperm in azoospermic individuals
Objective: In this study, specimens from testicular biopsies of men with nonobstructive azoospermia (NOA) were used to investigate whether RNF8 gene could serve as a biomarker to predict the presence of sperm in these patients.Methods: Testicular biopsy specimens from 47 patients were classified according to the presence of sperm (positive vs. negative groups) and investigated for the expression of RNF8. The level of RNF8 gene expression in the testes was compared between these groups using reverse-transcription polymerase chain reaction.Results: The expression level of RNF8 was significantly higher in testicular samples from the positive group than in those from the negative group. Moreover, the area under the curve of RNF8 expression for the entire study population was 0.84, showing the discriminatory power of RNF8 expression in differentiating between the positive and negative groups of men with NOA. A receiver operating characteristic curve analysis showed that RNF8 expression had a sensitivity of 81% and a specificity of 84%, with a cutoff level of 1.76.Conclusion: This study points out a significant association between the expression of RNF8 and the presence of sperm in NOA patients, which suggests that quantified RNF8 expression in testicular biopsy samples may be a valuable biomarker for predicting the presence of spermatozoa in biopsy samples.
- 31 March 2020
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 47 (1) , 61-67
Open AccessUpregulation of the RNF8 gene can predict the presence of sperm in azoospermic individuals
Objective: In this study, specimens from testicular biopsies of men with nonobstructive azoospermia (NOA) were used to investigate whether RNF8 gene could serve as a biomarker to predict the presence of sperm in these patients.Methods: Testicular biopsy specimens from 47 patients were classified according to the presence of sperm (positive vs. negative groups) and investigated for the expression of RNF8. The level of RNF8 gene expression in the testes was compared between these groups using reverse-transcription polymerase chain reaction.Results: The expression level of RNF8 was significantly higher in testicular samples from the positive group than in those from the negative group. Moreover, the area under the curve of RNF8 expression for the entire study population was 0.84, showing the discriminatory power of RNF8 expression in differentiating between the positive and negative groups of men with NOA. A receiver operating characteristic curve analysis showed that RNF8 expression had a sensitivity of 81% and a specificity of 84%, with a cutoff level of 1.76.Conclusion: This study points out a significant association between the expression of RNF8 and the presence of sperm in NOA patients, which suggests that quantified RNF8 expression in testicular biopsy samples may be a valuable biomarker for predicting the presence of spermatozoa in biopsy samples.
- Open Access
- 1 March 2020
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 13, 89-97
Major miRNA Involved in Insulin Secretion and Production in Beta-Cells
Insulin is implicated as a leading factor in glucose homeostasis and an important theme in diabetes mellitus (DM). Numerous proteins are involved in insulin signaling pathway and their dysregulation contributes to DM. microRNAs (miRNAs) as single-strand molecules have a critical effect on gene expression at post-transcriptional levels. Intensive investigation done by DM researchers disclosed that miRNAs have a significant role in insulin secretion by direct targeting numerous proteins engaged in insulin signaling pathway; so, their dysregulation contributes to DM. In this review, we presented some major miRNAs engaged in the insulin production and secretion.
- 1 March 2020
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 13, 89-97
Open AccessMajor miRNA Involved in Insulin Secretion and Production in Beta-Cells
Insulin is implicated as a leading factor in glucose homeostasis and an important theme in diabetes mellitus (DM). Numerous proteins are involved in insulin signaling pathway and their dysregulation contributes to DM. microRNAs (miRNAs) as single-strand molecules have a critical effect on gene expression at post-transcriptional levels. Intensive investigation done by DM researchers disclosed that miRNAs have a significant role in insulin secretion by direct targeting numerous proteins engaged in insulin signaling pathway; so, their dysregulation contributes to DM. In this review, we presented some major miRNAs engaged in the insulin production and secretion.
- Open Access
- 14 February 2020
- Published by Springer Nature in BMC Medical Genetics
- Vol. 21 (1) , 1-7
Testicular expression of TDRD1, TDRD5, TDRD9 and TDRD12 in azoospermia
Background: Tudor domain-containing proteins (TDRDs) play a critical role in piRNA biogenesis and germ cell development. piRNAs, small regulatory RNAs, act by silencing of transposons during germline development and it has recently been shown in animal model studies that defects in TDRD genes can lead to sterility in males. Methods: Here we evaluate gene and protein expression levels of four key TDRDs (TDRD1, TDRD5, TDRD9 and TDRD12) in testicular biopsy samples obtained from men with obstructive azoospermia (OA, n = 29), as controls, and various types of non-obstructive azoospermia containing hypospermatogenesis (HP, 28), maturation arrest (MA, n = 30), and Sertoli cell-only syndrome (SCOS, n = 32) as cases. One-way ANOVA test followed by Dunnett’s multiple comparison post-test was used to determine inter-group differences in TDRD gene expression among cases and controls. Results: The results showed very low expression of TDRD genes in SCOS specimens. Also, the expression of TDRD1 and TDRD9 genes were lower in MA samples compared to OA samples. The expression of TDRD5 significantly reduced in SCOS, MA and HP specimens than the OA specimens. Indeed, TDRD12 exhibited a very low expression in HP specimens in comparison to OA specimens. All these results were confirmed by Western blot technique. Conclusion: TDRDs could be very important in male infertility, which should be express in certain stages of spermatogenesis.
- 14 February 2020
- Published by Springer Nature in BMC Medical Genetics
- Vol. 21 (1) , 1-7
Open AccessTesticular expression of TDRD1, TDRD5, TDRD9 and TDRD12 in azoospermia
Background: Tudor domain-containing proteins (TDRDs) play a critical role in piRNA biogenesis and germ cell development. piRNAs, small regulatory RNAs, act by silencing of transposons during germline development and it has recently been shown in animal model studies that defects in TDRD genes can lead to sterility in males. Methods: Here we evaluate gene and protein expression levels of four key TDRDs (TDRD1, TDRD5, TDRD9 and TDRD12) in testicular biopsy samples obtained from men with obstructive azoospermia (OA, n = 29), as controls, and various types of non-obstructive azoospermia containing hypospermatogenesis (HP, 28), maturation arrest (MA, n = 30), and Sertoli cell-only syndrome (SCOS, n = 32) as cases. One-way ANOVA test followed by Dunnett’s multiple comparison post-test was used to determine inter-group differences in TDRD gene expression among cases and controls. Results: The results showed very low expression of TDRD genes in SCOS specimens. Also, the expression of TDRD1 and TDRD9 genes were lower in MA samples compared to OA samples. The expression of TDRD5 significantly reduced in SCOS, MA and HP specimens than the OA specimens. Indeed, TDRD12 exhibited a very low expression in HP specimens in comparison to OA specimens. All these results were confirmed by Western blot technique. Conclusion: TDRDs could be very important in male infertility, which should be express in certain stages of spermatogenesis.
- Top Cited PapersOpen Access
- 1 February 2020
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 13, 29-41
Some of the Factors Involved in Male Infertility: A Prospective Review
Infertility is defined as the inability of couples to have a baby after one year of regular unprotected intercourse, affecting 10 to 15% of couples. According to the latest WHO statistics, approximately 50– 80 million people worldwide sufer from infertility, and male factors are responsible for approximately 20– 30% of all infertility cases. The diagnosis of infertility in men is mainly based on semen analysis. The main parameters of semen include: concentration, appearance and motility of sperm. Causes of infertility in men include a variety of things including hormonal disorders, physical problems, lifestyle problems, psychological issues, sex problems, chromosomal abnormalities and single-gene defects. Despite numerous efforts by researchers to identify the underlying causes of male infertility, about 70% of cases remain unknown. These statistics show a lack of understanding of the mechanisms involved in male infertility. This article focuses on the histology of testicular tissue samples, the male reproductive structure, factors affecting male infertility, strategies available to find genes involved in infertility, existing therapeutic methods for male infertility, and sperm recovery in infertile men.
- 1 February 2020
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 13, 29-41
Top Cited PapersOpen AccessSome of the Factors Involved in Male Infertility: A Prospective Review
Infertility is defined as the inability of couples to have a baby after one year of regular unprotected intercourse, affecting 10 to 15% of couples. According to the latest WHO statistics, approximately 50– 80 million people worldwide sufer from infertility, and male factors are responsible for approximately 20– 30% of all infertility cases. The diagnosis of infertility in men is mainly based on semen analysis. The main parameters of semen include: concentration, appearance and motility of sperm. Causes of infertility in men include a variety of things including hormonal disorders, physical problems, lifestyle problems, psychological issues, sex problems, chromosomal abnormalities and single-gene defects. Despite numerous efforts by researchers to identify the underlying causes of male infertility, about 70% of cases remain unknown. These statistics show a lack of understanding of the mechanisms involved in male infertility. This article focuses on the histology of testicular tissue samples, the male reproductive structure, factors affecting male infertility, strategies available to find genes involved in infertility, existing therapeutic methods for male infertility, and sperm recovery in infertile men.